Special Report Download

Alzheimer’s Disease Medication: A Comparative Safety Analysis

Alzheimer's Disease Medication Safety Analysis

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by brain cell death and decreased communication between certain neuronal cells and across brain networks

FDA has approved 5 medications to treat people that have been diagnosed with AD. However, these drugs do not address the underlying pathology of the disease itself, do not inhibit progression, and cannot be considered curative.

Drugs included in the analysis are:

  • Exelon (rivastigmine)
  • Razadyne (galantamine hydrobromide)
  • Razadyne ER (galantamine hydrobromide)
  • Aricept (donepezil hydrochloride)
  • Namenda (memantine hydrochloride)
  • Namzaric (memantine hydrochloride and donepezil hydrochloride)

For full access to this free report, please complete the information on this page.

Please note: This is an independent analysis conducted by Advera Health, based upon data and insight generated by the analytical tools of AdverseEvents Explorer and other pertinent information gathered at the time of publication. This analysis is not sponsored or influenced by any third party. The inclusion of a particular company, drug, adverse event, class or indication in this report is determined wholly by our quantitative signaling and analytic systems along with our qualitative analysis work.